Latest Strategy Changes News

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Westgold Resources reported a record A$80 million increase in cash, bullion, and liquid investments in Q3 FY25, maintaining steady gold production and cost guidance while advancing key mine ramp-ups and strategic divestments.

Barton Gold Holdings reported a 120,000-ounce gold resource increase at Tunkillia and uncovered exceptional high-grade silver at Tarcoola’s Tolmer prospect, alongside a $3.1 million half-year profit and accelerated feasibility studies.

Kalgoorlie Gold Mining’s March quarter was marked by a breakthrough Lighthorse gold discovery at the Pinjin Project, confirmed by RC drilling and supported by a strengthened balance sheet. The company is poised to expand exploration across its Laverton Tectonic Zone tenure.

European Lithium Limited reports a maiden 45 million tonne rare earth resource at its Greenland Tanbreez Project, alongside a $24.5 million capital raise by its majority-owned Critical Metals Corp, underpinning its global lithium and rare earth ambitions.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Jupiter Mines reported a robust Q3 FY2025 with higher manganese production and sales at Tshipi, driving a 65% jump in EBITDA amid improved prices and reduced costs.

Northern Minerals has made significant progress on its Browns Range Heavy Rare Earths Project, advancing its feasibility study and exploration while raising $41.5 million, positioning itself as a strategic alternative amid growing geopolitical supply risks.

AnteoTech Ltd reports progress in advanced battery and life sciences technologies alongside a strategic review and leadership changes amid challenging EV market conditions.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Syntara Limited reports significant clinical progress with its lead myelofibrosis drug SNT-5505 and launches a new trial for its next-generation anti-fibrotic skin treatment, supported by a solid $18 million cash reserve.